NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test
Genedrive PLC (AIM:GDR) NICE issues Medtech Innovation Briefing
Genedrive® MT-RNR1 ID Kit Product – Video
World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss
Genedrive PLC (AIM:GDR) First NHS Deployments of Genedrive System for AIHL
First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss
Braveheart Inv Group (AIM: BRH) Operational update
Braveheart Investment Group plc (AIM: BRH), provides the following update on its investment portfolio and strategy.
Genedrive PLC (AIM: GDR) Update on Point of Care Covid Test
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on the progress being made on the Genedrive®COV19-ID kit, its rapid point of care molecular test for
Genedrive PLC (GDR.L) Investor Presentation
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2021 on Tuesday, 29 March 2022.
Braveheart Inv Group (BRH.L) Operational update on Paraytec
Braveheart Investment Group plc (AIM: BRH), is pleased to provide the following update on Paraytec, a company within the Group’s investment portfolio. Recent upgrades to the CX300 instrument indicate a
Genedrive PLC (GDR.L) UK CTDA application for Genedrive® COV19-ID kit
Sensitivity and specificity data submitted meets MHRA requirements
Genedrive PLC (GDR.L) CE-IVD certification for Point-of-Care Genedrive®COV19-ID kit
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to the announcement of 29 November 2021, its rapid point of care Genedrive®COV19-ID Kit has received CE-IVD
Genedrive PLC (GDR.L) POC kit submitted for CE-IVD certification
Point-of-care Genedrive®COV19-ID submitted for CE-IVD certification Sets new benchmark in speed, accuracy and ease of use
Genedrive PLC (GDR.L) Audited Final Results
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces its audited Final Results for the year ended 30 June 2021.
